Sanofi's New Polio Vaccine Approved in India
By Rediff Money Desk, NEWDELHI Apr 05, 2024 14:57
Sanofi has received approval for its IMOVAX-Polio vaccine in India, replacing ShanIPV. The new vaccine has been used globally for over 40 years and ensures continued polio protection.
New Delhi, Apr 5 (PTI) Drug firm Sanofi on Friday said it has obtained approval for IMOVAX-Polio, an alternative injectable vaccine, to replace the Inactivated Polio Vaccine (IPV) ShanIP in India.
IMOVAX-Polio is an alternative IPV vaccine that has been used in more than 100 countries for over 40 years, a Sanofi India spokesperson told PTI.
The vaccine has the same composition/formulation as ShanIPV, the spokesperson added.
"We wish to assure all stakeholders that there will be no shortage of IPV vaccines in India on our account, towards safeguarding the nation's status of remaining polio-free. We remain fully committed to fulfilling our public health mission in India," the spokesperson noted.
To ensure that there is no interruption to the availability of IPV vaccines, the French firm has already obtained approvals for IMOVAX-Polio.
"...Sanofi has had to adapt its strategy and portfolio to these (emerging) trends. Accordingly, Sanofi Healthcare India Pvt Ltd (SHIPL) announced that by the end of 2023, it will discontinue ShanIPV, which was only filled and packaged at our factory in Hyderabad, India," the spokesperson added.
Launched in India in 2015, ShanIPV is a trivalent inactivated injectable vaccine. Under the government's immunisation programme, the vaccine was injected in two stages at six weeks and 14 weeks of age.
Sanofi and Serum Institute of India are the leading suppliers of IPV vaccines in India.
IMOVAX-Polio is an alternative IPV vaccine that has been used in more than 100 countries for over 40 years, a Sanofi India spokesperson told PTI.
The vaccine has the same composition/formulation as ShanIPV, the spokesperson added.
"We wish to assure all stakeholders that there will be no shortage of IPV vaccines in India on our account, towards safeguarding the nation's status of remaining polio-free. We remain fully committed to fulfilling our public health mission in India," the spokesperson noted.
To ensure that there is no interruption to the availability of IPV vaccines, the French firm has already obtained approvals for IMOVAX-Polio.
"...Sanofi has had to adapt its strategy and portfolio to these (emerging) trends. Accordingly, Sanofi Healthcare India Pvt Ltd (SHIPL) announced that by the end of 2023, it will discontinue ShanIPV, which was only filled and packaged at our factory in Hyderabad, India," the spokesperson added.
Launched in India in 2015, ShanIPV is a trivalent inactivated injectable vaccine. Under the government's immunisation programme, the vaccine was injected in two stages at six weeks and 14 weeks of age.
Sanofi and Serum Institute of India are the leading suppliers of IPV vaccines in India.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.63 (+ 5.00)
- 35877604
- Vodafone Idea L
- 8.28 ( -0.96)
- 29713326
- Home First Finance
- 1,045.35 ( -0.68)
- 22438357
- G G Engineering
- 1.86 ( 0.00)
- 14057650
- Ola Electric Mobilit
- 91.38 (+ 4.53)
- 10478175
MORE NEWS
Ola Electric to Expand Store Network to 4,000...
Ola Electric plans to increase its store network to 4,000 by December 2024, expanding...
Housing Prices Surge 11% in 8 Cities, Delhi-NCR...
Indian housing market sees continued price growth, with Delhi-NCR leading at 32% in Q3...
Sustainable Consumption: Goyal Urges Carbon...
Commerce Minister Piyush Goyal calls for promoting sustainable consumption patterns to...